Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121
In new data from Icosavax's IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 μg unadjuvanted dosages) -
在 Icosavax 針對老年人的 IVX-121 1b 期延期試驗的新數據中，截至第 365 天，針對呼吸道合胞病毒的 GMT 在第 28 天持續在 GMT 的約 45-70%（75 和 250 微克未調整劑量）-
- Data provide additional clinical evidence of potential differentiation on durability with company's VLP platform technology -
-數據提供了額外的臨床證據，證明公司的 VLP 平台技術在耐久性方面存在潛在差異-
- Robust immune response against RSV-A observed in Phase 1b extension trial participants who were revaccinated with IVX-121 twelve months following initial dose -
-在初始劑量十二個月後重新接種 IVX-121 疫苗的 1b 期延期試驗參與者中觀察到對 RSV-A 的強大免疫反應-
- IVX-121 continues to be generally well tolerated with no additional safety concerns observed with longer-term follow up or revaccination -
-IVX-121 總體耐受性仍然良好，長期隨訪或重新接種疫苗後不會出現其他安全問題-
- IVX-A12 (a potential-first-in-class bivalent combination of IVX-121 for RSV and IVX-241 for hMPV) currently in a Phase 2 trial; Phase 2 topline interim data now expected by end 2023 -
-IVX-A12（一種潛在的同類首創雙價組合，用於呼吸道合胞病毒，IVX-241 用於呼吸道合胞病毒）目前正在進行二期試驗；現在預計將在2023年底發佈第二階段的中期數據-IVX-121